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ORIGINAL ARTICLE
Prevalence and predictors of complementary and alternative medicine/
non-pharmacological interventions use for menopausal symptoms within
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Copenhagen, Copenhagen, Denmark; cUNSW Australia, Sydney, Australia; dCentre for Women's Health, Institute of Human Development,
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ABSTRACT
Objectives: The negative publicity about menopausal hormone therapy (MHT) has led to increased
use of complementary and alternative medicines (CAM) and non-pharmacological interventions (NPI)
for menopausal symptom relief. We report on the prevalence and predictors of CAM/NPI among UK
postmenopausal women.
Method: Postmenopausal women aged 50–74 years were invited to participate in the UK Collaborative
Trial of Ovarian Cancer Screening (UKCTOCS). A total of 202 638 women were recruited and completed
a baseline questionnaire. Of these, 136 020 were sent a postal follow-up-questionnaire between
September 2006 and May 2009 which included ever-use of CAM/NPI for menopausal symptom relief.
Both questionnaires included MHT use.
Results: A total of 88 430 (65.0%) women returned a completed follow-up-questionnaire; 22 206
(25.1%) reported ever-use of one or more CAM/NPI. Highest use was reported for herbal therapies
(43.8%; 9725/22 206), vitamins (42.6%; 9458/22 206), lifestyle approaches (32.1%; 7137/22 206) and phy-
toestrogens (21.6%; 4802/22 206). Older women reported less ever-use of herbal therapies, vitamins
and phytoestrogens. Lifestyle approaches, aromatherapy/reflexology/acupuncture and homeopathy
were similar across age groups. Higher education, Black ethnicity, MHT or previous oral contraceptive
pill use were associated with higher CAM/NPI use. Women assessed as being less hopeful about their
future were less likely to use CAM/NPI.
Conclusion: One in four postmenopausal women reported ever-use of CAM therapies/NPI for meno-
pausal symptom relief, with lower use reported by older women. Higher levels of education and pre-
vious MHT use were positive predictors of CAM/NPI use.
UKCTOCS Trial registration: ISRCTN22488978
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Introduction
In 2002, the US Women’s Health Initiative (WHI) reported that
menopausal hormone therapy (MHT) was associated with an
increased risk of breast cancer, cardiovascular disease and
thromboembolic events1. The negative publicity that ensued
alarmed many women and their clinicians, resulting in a
decrease in MHT use across the world2–6. A similar trend was
observed in postmenopausal women taking part in the United
Kingdom Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS); MHT use decreased in women recruited in 2005
(10–11%) compared with those recruited in 2001 (29%)7.
Complementary and alternative medicine (CAM) for meno-
pausal symptom relief is by definition not considered part of
conventional medicine8. The lay public regard them as being
‘fairly safe’9. They can include approaches such as herbal
therapies, phytoestrogens, and non-pharmacological inter-
ventions (NPI) such as exercise, acupuncture and yoga.
Cognitive behavior therapy is considered part of conven-
tional medicine and has been recommended by the National
Institute of Health and Care Excellence (NICE) for manage-
ment of low mood associated with the menopause10.
Two systematic reviews of use of CAM therapies for meno-
pausal symptoms have been published. The first in 2013,
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based on nine studies with a total of 32 465 menopausal
women, reported that 50.5% used CAM therapies/NPI for
relief of menopausal symptoms11. The more recent 2014
meta-analysis restricted eligible studies to those involving
more than 500 women and reported a CAM/NPI prevalence
ranging from 31% to 82.5%12. Both reviews conclude that
many surveys were of poor methodological quality, making it
difficult to estimate the true prevalence of CAM/NPI use
among climacteric women11,12.
Data from the UK are limited to three surveys, two of
which were undertaken in 2001 before the publication of the
WHI results. The remaining survey dates from 2006 involving
563 women. The overall prevalence of CAM/NPI use was not
reported but the prevalence of each CAM therapy ranged
from 1.2% for hypnosis to 39.6% for vitamins13.
Higher income, education and socioeconomic status have
been shown to predict CAM/NPI use14,15 with CAM/NPI con-
sumers also using more conventional therapies than women
not using CAM/NPI. Other factors associated with use of
CAM/NPI therapies in the UK are White ethnicity, being phys-
ically active and a non-smoker13.
We report on the prevalence and predictors of CAM and
NPI use for relief of menopausal symptoms in a large UK
cohort of postmenopausal women participating in UKCTOCS.
Methods
Study participants
UKCTOCS is a randomized controlled trial designed to assess
the impact on mortality of ovarian cancer screening.
Between April 2001 and October 2005, postmenopausal
women aged 50–74 were randomly invited from age-sex
registers and 202 638 enrolled through 13 trial centers
located in NHS Trusts in England, Wales and Northern
Ireland. Further details on the study design have been
reported elsewhere16. Postmenopausal status in these
women aged over 50 was defined as >12 months amenor-
rhea following a natural menopause or hysterectomy or
>12 months of MHT commenced for menopausal symptoms.
All women completed a baseline questionnaire at recruit-
ment which included questions on current use of MHT, date
of last period, age at first menstrual period, oral contracep-
tive pill (OCP) use, hysterectomy, sterilization, infertility, preg-
nancies lasting less or more than 6 months, personal history
of cancer and family history of ovarian and breast cancer.
All women were followed up with a postal questionnaire
(FUQ) 3–5 years after randomization. From September 2006,
the FUQ included the question ‘Have you used any of the
following to relieve menopausal symptoms?’ (yes or no) with
a tick for each of the following: (1) herbal remedies, e.g.
black cohosh; (2) phytoestrogens or soy products; (3) vita-
mins, e.g. Menopace, vitamin E; (4) homeopathic remedies;
(5) aromatherapy, reflexology or acupuncture; (6) lifestyle
changes, e.g. relaxation, exercise; or (7) other medical treat-
ments, e.g. Venlafaxine, Megace.
Also included in the FUQ were questions on education,
alcohol use, smoking, chronic diseases (diabetes, high blood
pressure, high cholesterol, heart disease, stroke, rheumatoid
arthritis, osteoarthritis, osteoporosis), cancers diagnosed after
trial entry, and current MHT use. Women’s broad expecta-
tions about the future and their perceived ability to attain
personal goals were assessed with two statements: ‘The
future seems to me to be hopeful, and I believe that things
are changing for the better’ and ‘I feel that it is possible to
reach the goals I would like to strive for’. Women were asked
to indicate the extent to which they agreed with each state-
ment using a 5-item scale from ‘absolutely agree’ to
‘absolutely disagree’ where higher scores indicate higher
levels of hopelessness. This positively phrased measure of
hopelessness has been shown to be valid and reliable in
postmenopausal women in the UK17.
Ethical approval for the study was received from the
UCL/UCLH Committees on the Ethics of Human Research,
Committee A on 30th May 2006 (REC 06/Q0505/36).
Statistical analysis
Predictors of CAM/NPI use
With regard to the demographic variables, erroneous heights
<120 cm and >210 cm and weights <30 and >200 kg were
discarded and the data field set as missing. The body mass
index (BMI) was either grouped as: underweight (< 20 kg/m2);
normal weight (20 and <25 kg/m2); overweight (25 and
<30 kg/m2); obese (30 and <40 kg/m2); and morbidly obese
( 40 kg/m2) or used as a continuous variable. Ethnicity was
grouped as White, Black (which included Black African, Black
Caribbean and Black Other), South Asian (Indian, Pakistani
and Bangladeshi) and Other. Education was grouped as
Higher education (college/university), Other formal qualifica-
tion (nursing and teaching, ‘O’ level or equivalent, ‘A’ level or
equivalent and clerical or commercial qualification) or No for-
mal qualification (other than compulsory education). Women
who had stated that they had both college/university degree
and no formal education (n¼ 120) were grouped under col-
lege/university.
Use of CAM/NPI (yes/no and type) were examined by age
group, ethnicity, education, BMI, OCP use, MHT use, hysterec-
tomy, sterilization, number of pregnancies and cancer history.
For the women residing in England, an Index of Multiple
Deprivation (IMD) score based on the women’s postcode
derived at the Super Output Area level was available and
used as a proxy for the socioeconomic status. For reasons of
model interpretation, the IMD score was standardized to
have a standard deviation of one.
Women who had used both CAM/NPI and ‘other medical
treatments’ were not included in the model, but were
adjusted for in the regression analysis.
Multivariate probit model of predictors of CAM/NPI use
for women residing in England
To examine the associations between the six different types
of CAM/NPI, tetrachoric correlations of CAM/NPI type use
were calculated, which estimate the correlation between two
theorized normally distributed latent variables (here the pro-
pensity for CAM/NPI type use) using observed dichotomous
variables. Similarly to other correlational measures, possible
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values ranged from 1 (negative correlation) to þ1 (positive
correlation). To model the effect of the various factors on the
probability of each CAM/NPI type use, it was necessary to
account for the likelihood that CAM/NPI use for one type will
be highly (positively) correlated with each of the other
CAM/NPI types. For this reason, a multivariate probit model
was fitted (with the user-written command mvprobit in
Stata18) which preserved this correlational structure in the
six-dimensional response variable.
Age (stratified per 5-year age groups), BMI (per 5 kg/m2),
age at first menstrual period (FMP, per 5 years), age at last
menstrual period (LMP, per 5 years), hopelessness (HH, per
unit SD), IMD score (per unit SD), number of pregnancies
<6 months and number of pregnancies >6 months were
modeled as continuous variables. Univariate probit models
were used to check the functional form and demonstrate
that linearity (in the probit scale) was a reasonable
assumption.
As probit model parameters are not easily interpretable,
marginal effects were estimated using Stata’s margin and lin-
com commands. Given that the model had 180 parameter esti-
mates, the marginal effect (with 95% confidence interval (CI))
on each CAM/NPI type was also plotted in variable groupings
to improve interpretation. Formal hypothesis testing was not
considered due to the number of model estimates.
Results
Between September 2006 and May 2009, 136 020 postmeno-
pausal women taking part in UKCTOCS were sent a follow-up
questionnaire assessing use of CAM/NPI for relief of meno-
pausal symptoms; 96 428 women returned a questionnaire
(70.9%). A total of 7057 women were excluded from the ana-
lysis as the questionnaire completion date was missing. Of
the remaining 89 371 participants, 941 had used ‘other med-
ical treatment’ and were excluded. The final cohort included
88 430 (65.0%) cases. The overall median age was 64.7 years,
with all women aged over 51 at completion of the survey;
97.4% (86 116/88 430) were White and 21.4% (18 902/88 430)
had a higher education (Table 1).
Ever-use of CAM/NPI
Of all the women who completed the questionnaire, 25.1%
(22 206/88 430) reported ‘ever-use’ of at least one of the six
types of CAM/NPI for menopausal symptom relief (Table 1).
The prevalence of CAM/NPI use across responders ranged
from 3.2% (2791/88 430) for homeopathy to 11.0% (9725/
88 430) for herbal remedies. In those reporting CAM/NPI use,
the most commonly used therapies were herbal remedies
(43.8%; 9725/22 206), vitamins (42.6%; 9458/22 206) and life-
style changes (32.1%; 7137/22 206) followed by phytoestro-
gens (21.6%; 4802/22 206). A smaller percentage of women
used aromatherapy/reflexology/acupuncture (ARA) (14.6%;
3236/22 206) and homeopathy (12.6%; 2791/22 206) (Table 1).
Of the 4780 (5.4%) who reported a history of breast can-
cer, 8.3% (396/4780) had used MHT and 21.1% (1008/4780)
had used one of the CAM/NPI.
Of the women who had ever-used CAM/NPI, 57.6%
(12 799/22 206) indicated they had only used one type of
therapy, with herbal remedies being most frequently used
(3965), 25.9% (5756/22 206) had used two therapies with a
combination of herbal remedies and vitamins (1254) most
commonly used. Three or more therapies were used by
16.4% (3651/22 206) of the women (data not shown).
Correlations between CAM/NPI types
Correlations between the six different types of CAM/NPI were
examined using tetrachoric correlations. All observed correla-
tions were strong, with a minimum of 0.39 (herbal and life-
style) and a maximum of 0.64 (herbal and phytoestrogens).
Other correlations over 0.6 were for ARA and homeopathy
(0.61) and lifestyle and ARA (0.63). These unadjusted tet-
rachoric correlations are shown in the lower triangle of
Supplementary Table S1 (see http://dx.doi.org/10.1080/
13697137.2017.1301919). The upper triangle gives the
between CAM/NPI type correlations estimated following
adjustment from the model and are largely similar to the
unadjusted correlations, though mostly slightly lower.
Predictors of CAM/NPI use
Due to the inclusion of the deprivation (IMD) variable based
on women who resided in England, the modeling was
restricted to 66 577 cases. There were missing covariate data
in 7053 cases and excluding these meant that 59 524 cases
were included in the final model. For each potential pre-
dictor, Figure 1 depicts the estimated effect on probability of
ever-use of each CAM/NPI type for a unit change in that pre-
dictor, with 95% CIs. The actual values that underlie this plot
are presented in Supplementary Table S2 (see http://dx.doi.
org/10.1080/13697137.2017.1301919), and the original model
estimates in the probit scale are presented in Supplementary
Table S3 (see http://dx.doi.org/10.1080/13697137.2017.
1301919).
There was a wide range of effect across the predictors
with some having an unequivocal effect on CAM/NPI use and
some being only minimally related to CAM/NPI use. In add-
ition, it was notable that some predictors had a consistent
effect across the six CAM/NPI types whilst others had a dis-
crepant effect. In general, the predictors for herbal remedies
were often quite different to those for the other CAM/NPIs,
an effect which was also observed for lifestyle changes but
to a lesser extent.
Age was a strong negative predictor of ever-use of CAM/
NPI types, especially herbal remedies (each 5-year increase in
age reduced ever-use by 5.4% (95% CI 5.1–5.7%) (Figure 1).
This is also apparent in the overall set of 22 206 women
(Table 1). With increasing age, there was a decline in ever-
use of herbal remedies and vitamins and a less pronounced
decline in ever-use of phytoestrogens (Figure 1). The uses of
ARA, homeopathy and lifestyle change were similar across all
the age groups (Figure 1).
Other consistently negative predictors were BMI (each
additional 5 kg/m2 reduced most CAM/NPI type use by
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around 1%), high blood pressure and diabetes. Hopelessness
(HH) had a small but clear negative effect on use of all CAM/
NPI types. Women who had a low HH score (more hopeful)
were more likely to use any CAM/NPI to relieve menopausal
symptoms, with lifestyle changes being the most likely.
Interestingly, the number of full-term pregnancies had a con-
sistent negative effect across CAM/NPI types, whereas the
number of pregnancies under 6 months had a consistent
positive effect on CAM/NPI usage (around 0.5% per
pregnancy).
Age at last menstrual period had a consistent positive
effect on CAM/NPI usage (ranging from 0.2% for ARA to
1.4% for herbal remedies for each 5-year increase). Other
clear positive effects were also found with osteoarthritis,
MHT use (though much higher for herbal remedies), higher
education (though much higher for lifestyle changes), other
formal qualifications and being of Black ethnicity. OCP use
had a positive effect on all CAM/NPI types but the effect
was only unequivocal for herbal remedies (1.8%; 95% CI
1.2–2.4%).
Some predictors had a less consistent effect across the six
CAM/NPI types, notably previous cancer only negatively
affecting use of herbal remedies and to a lesser extent vita-
mins, and both osteoporosis, South Asian and ‘Other’ ethni-
city appearing to have a negative effect on use of herbal
remedies and a positive effect on lifestyle changes.
Discussion
In our study of over 88 000 postmenopausal women, which
to our knowledge is the largest report on the subject, one in
four women used at least one CAM therapy/NPI for meno-
pausal symptom relief. Herbal therapies and vitamins were
most commonly used followed by lifestyle approaches.
Higher levels of education and previous MHT use were posi-
tive predictors of CAM/NPI use while women who were over-
weight or obese, had diabetes/hypertension or held less
hopeful views about the future and their ability to achieve
personal goals were less likely to use CAM/NPI.
Previous studies have reported CAM use to range from
24% to 91%13. The prevalence in our study (25%) was mark-
edly lower than the 57% reported in a recent meta-analysis
of three UK studies involving 3742 climacteric women14.
However, two of these studies were undertaken prior to the
publication of the WHI results in 2002.
Herbal remedies were most commonly used, as reported
in other studies19–21, followed by vitamins and lifestyle
changes. This trend persisted on subgroup analysis restricted
to women who had only used one approach and is in keep-
ing with results of a 2013 systematic review11. It needs to be
noted, however, that some of the vitamin preparations may
have contained phytoestrogens. One in five of the CAM users
opted for a lifestyle change while one in four used at least
two different types of CAM.
The association of age with type of CAM/NPI use for
menopausal symptom relief is likely to be a cohort effect.
Women of all age groups reported similar use of aromather-
apy/reflexology/acupuncture, homeopathy and lifestyle
changes for relief of menopausal symptoms. These
approaches have been in use since the 1960s and are there-
fore likely to have been available when older women in our
cohort were going through the menopause. In contrast,
younger women reported higher ever-use of herbal remedies,
vitamins and phytoestrogens, reflecting the more recent
popularity of these regimes.
Consistent with the existing literature19,22–24, higher edu-
cation positively influenced CAM/NPI use. This may reflect
a greater propensity to seek out health information (books,
magazines, internet), leading to greater knowledge on the
availability of CAM for menopausal symptom relief21.
Alternatively, as women with a higher level of education
have been shown to have less severe hot flushes and
night sweats25, it is possible that milder symptoms may
have contributed to the decision to use CAM/NPI rather
than MHT.
The financial cost of these therapies is known to influence
women’s choices26. However, our data do not show a clear
association between socioeconomic status, based on the
deprivation (IMD) score, and use of CAM therapies/NPI for
menopausal symptoms, which is at odds with previous
reports14,27,28. Only phytoestrogens, and to some extent life-
style changes, were less likely to be used with increasing
deprivation.
A variety of other factors predicted CAM/NPI use with
some having an unequivocal effect whilst others had only a
minimal impact. Interestingly, predictors of herbal remedy
use were often quite different to the others. In contrast to
the results reported by the Study of Women’s Health across
the Nation (SWAN)14, we found higher BMI to be negatively
associated with ever use of CAM/NPI. A similarly negative
correlation was also seen in those reporting hypertension
and diabetes. CAM/NPI users have previously been described
to smoke less29 but we were not able to confirm this in our
cohort. Although being of Black ethnicity was a strong pre-
dictor of CAM/NPI use, there were only 294 women in this
group representing 1.3% of CAM/NPI users.
There is a large body of evidence suggesting that hope-
lessness is related to the development and outcome of men-
tal and physical health conditions, ranging from depression
to cardiovascular disease and cancer30–37. Women who were
less hopeful about the future and their ability to attain per-
sonal goals were less likely to use any CAM/NPI and had the
lowest use of lifestyle approaches to relieve menopausal
symptoms. Previous studies have suggested that people who
see their medical symptoms as an opportunity for personal
development and learning are more likely to use CAMs38.
Furthermore, studies in cancer patients have shown that
many consider use of CAMs in addition to standard medical
methods as one way of coping and actively addressing feel-
ings of hopelessness39.
Use of MHT (as in the SWAN study)27 and OCP positively
predicted CAM/NPI ever use with the largest effect seen for
herbal remedies. It is likely that women who are proactive in
taking medicines to take control of their health are more
likely to use CAM/NPI. Many women in our cohort stopped
using MHT following the negative publicity of the 2002 WHI
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results1. It is possible that these women subsequently chose
CAM/NPI as an alternative for menopausal symptom relief40.
Despite the negative publicity surrounding MHT and the
initial scare about an increase in breast cancer risk, previous
cancer history did not predict overall CAM/NPI use. Of the
women with breast cancer history, 21% reported use of any
CAM/NPI type, which is similar to the usage across the entire
cohort. This is in keeping with the recommendation that
women with a history of breast cancer should consider non-
hormonal options41.
Since the initial WHI report, the re-analysis of the trial data42
and subsequent studies have shown very beneficial risk–bene-
fit ratios for healthy women aged 50–60 years. In 2016, the
International Menopausal Society43 and NICE44 issued compre-
hensive guidance on use of MHT that reflects this revised per-
spective. It is likely that this may reverse the cycle of falling
MHT and increasing CAM/NPI use. Currently, the North
American Menopause Society only recommends cognitive
behavioral therapy and clinical hypnosis as non-hormonal,
non-medicinal approaches for menopausal symptom relief45.
Strengths and limitations
A key strength of our study is its size. The findings are likely
to be more representative of CAM/NPI use in postmeno-
pausal women in the general population, as self-selection
bias in this large cohort taking part in a screening trial is
likely to be less than in small studies focusing on the meno-
pause. It is also likely that self-reporting in a clinical trial set-
ting facilitated reporting of CAM/NPI use, as reports suggest
that 55–72% of women do not wish to discuss/disclose CAM
use to their health-care professionals46,47. A limitation in
keeping with all patient surveys is that the reported CAM/NPI
prevalence could have been influenced by a healthy volun-
teer effect48. We also had an overrepresentation of White
ethnicity in our cohort (97%) compared with the 2011
Census (92.1%)49. While we have not reported on the dur-
ation of use and efficacy of CAM/NPI across the whole
cohort, this has been reported in a subgroup of 10 000 par-
ticipants who consented to a more detailed study40.
Conclusion
One in four postmenopausal women in the UK reported use
of CAM/NPI for relief of menopausal symptoms, with herbal
remedies being most commonly used. Higher CAM/NPI use
was reported by women currently in their fifties and sixties.
Higher education, Black ethnicity, MHT and OCP use were
associated with higher CAM/NPI use while increasing BMI
and diabetes/hypertension were associated with less use.
Women who were less hopeful about the future and their
ability to attain personal goals were less likely to use any
type of CAM/NPI and had the lowest use of lifestyle
approaches to relieve menopausal symptoms.
Acknowledgements
We are particularly grateful to the women throughout the UK who are
participating in UKCTOCS and to the entire medical, nursing, and
administrative staff who work on the trial. We thank all the staff involved
in the trial for their hard work and dedication. We thank the members of
the Data Monitoring and Ethics Committee and the independent Trial
Steering Committee. Ethical approval: The study was approved on the 30
May 2006 by The Joint UCL/UCLH Committees on the Ethics of Human
Research (Committee A), REC Reference: 06/Q0505/36.
Conflict of interest U.M. and I.J. have a financial interest through
Abcodia Ltd in the third-party exploitation of the UKCTOCS biobank. I.J.
is a co-inventor of the ‘Risk of Ovarian Cancer Algorithm’, which has
been licensed to Abcodia. The remaining authors declare no conflict of
interest.
Source of funding UKCTOCS was funded by the Medical Research
Council (G9901012, G0801228), Cancer Research UK (C1479/A2884), and
the Department of Health, with additional support from The Eve Appeal.
Researchers at UCL were supported by the National Institute for Health
Research (NIHR) University College London Hospitals (UCLH) Biomedical
Research Centre. The funding source or the sponsor had no role in data
collection, data analysis, data interpretation, or writing of the report. The
researchers are independent from the funders.
References
1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of
estrogen plus progestin in healthy postmenopausal women: prin-
cipal results from the Women’s Health Initiative randomized con-
trolled trial. JAMA 2002;288:321–33
2. Hersh AL, Stefanick ML, Stafford RS. National use of postmeno-
pausal hormone therapy: annual trends and response to recent
evidence. JAMA 2004;291:47–53
3. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in
the use of postmenopausal hormone therapy after the publication
of clinical trial results. Ann Intern Med 2004;140:184–8
4. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy pre-
scribing patterns in the United States. Obstet Gynecol 2004;104:
1042–50
5. Faber A, Bouvy ML, Loskamp L, et al. Dramatic change in prescrib-
ing of hormone replacement therapy in The Netherlands after
publication of the Million Women Study: a follow-up study. Br J
Clin Pharmacol 2005;60:641–7
6. Gayet-Ageron A, Amamra N, Ringa V, et al. Estimated numbers of
postmenopausal women treated by hormone therapy in France.
Maturitas 2005;52:296–305
7. Menon U, Burnell M, Sharma A, et al. Decline in use of hormone
therapy among postmenopausal women in the United Kingdom.
Menopause 2007;14:462–7
8. Complementary, Alternative, or Integrative Health: What’s In a
Name? Available at: https://nccih.nih.gov/health/integrative-health.
Accessed 26 January 2017
9. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and
prevalence of alternative medicine. Prev Med 2002;35:166–73
10. NICE issues first guideline on menopause to stop women
suffering in silence. Available at: https://www.nice.org.uk/news/
press-and-media/nice-issues-first-guideline-on-menopause-to-stop-
women-suffering-in-silence. Accessed 26 January 2017
11. Posadzki P, Lee MS, Moon TW, et al. Prevalence of complementary
and alternative medicine (CAM) use by menopausal women: a sys-
tematic review of surveys. Maturitas 2013;75:34–43
12. Peng W, Adams J, Sibbritt DW, Frawley JE. Critical review of com-
plementary and alternative medicine use in menopause: focus on
prevalence, motivation, decision-making, and communication.
Menopause 2014;21:536–48
13. Daley A, MacArthur C, McManus R, et al. Factors associated with
the use of complementary medicine and non-pharmacological
interventions in symptomatic menopausal women. Climacteric
2006;9:336–46
246 A. GENTRY-MAHARAJ ET AL.
14. Bair YA, Gold EB, Azari RA, et al. Use of conventional and comple-
mentary health care during the transition to menopause: longitu-
dinal results from the Study of Women’s Health Across the Nation
(SWAN). Menopause 2005;12:31–9
15. Harris PE, Cooper KL, Relton C, Thomas KJ. Prevalence of comple-
mentary and alternative medicine (CAM) use by the general popu-
lation: a systematic review and update. Int J Clin Practice
2012;66:924–39
16. Menon U, Gentry-Maharaj A, Ryan A, et al. Recruitment to multi-
centre trials-lessons from UKCTOCS: descriptive study. BMJ (Clin
Res Ed) 2008;337:a2079
17. Fraser L, Burnell M, Salter LC, et al. Identifying hopelessness in
population research: a validation study of two brief measures of
hopelessness. BMJ Open 2014;4:e005093
18. Multivariate probit regression using simulated maximum likeli-
hood. Available at: http://www.stata-journal.com/article.html? arti-
cle¼st0045. Accessed 26 January 2017
19. Gollschewski S, Anderson D, Skerman H, Lyons-Wall P. Associations
between the use of complementary and alternative medications
and demographic, health and lifestyle factors in mid-life Australian
women. Climacteric 2005;8:271–8
20. Cardini F, Lesi G, Lombardo F, van der Sluijs C. The use of comple-
mentary and alternative medicine by women experiencing meno-
pausal symptoms in Bologna. BMC Womens Health 2010;10:7
21. Duffy OK, Iversen L, Hannaford PC. The impact and management
of symptoms experienced at midlife: a community-based study of
women in northeast Scotland. BJOG 2012;119:554–64
22. Lunny CA, Fraser SN. The use of complementary and alternative
medicines among a sample of Canadian menopausal-aged
women. J Midwifery Womens Health 2010;55:335–43
23. Bair YA, Gold EB, Greendale GA, et al. Ethnic differences in use of
complementary and alternative medicine at midlife: longitudinal
results from SWAN participants. Am J Public Health 2002;92:
1832–40
24. Newton KM, Buist DS, Keenan NL, et al. Use of alternative thera-
pies for menopause symptoms: results of a population-based sur-
vey. Obstet Gynecol 2002;100:18–25
25. Hunter MS, Gentry-Maharaj A, Ryan A, et al. Prevalence, frequency
and problem rating of hot flushes persist in older postmenopausal
women: impact of age, body mass index, hysterectomy, hormone
therapy use, lifestyle and mood in a cross-sectional cohort study
of 10,418 British women aged 54-65. BJOG 2012;119:40–50
26. Daoust JL, Mercer LC, Duncan AM. Prevalence of natural health
product use in healthy postmenopausal women. Menopause
2006;13:241–50
27. Bair YA, Gold EB, Zhang G, et al. Use of complementary and alter-
native medicine during the menopause transition: longitudinal
results from the Study of Women’s Health Across the Nation.
Menopause 2008;15:32–43
28. Dailey RK, Neale AV, Northrup J, et al. Herbal product use and
menopause symptom relief in primary care patients: a MetroNet
study. J Womens Health (Larchmt) 2003;12:633–41
29. Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmeno-
pausal hormone therapy: an observational study of tapering versus
quitting cold turkey: is there a difference in recurrence of meno-
pausal symptoms?. Menopause 2009;16:494–9
30. Alloy LB, Abramson LY, Metalsky GI, Hartlage S. The hopelessness
theory of depression: attributional aspects. Br J Clin Psychol/Br
Psychol Soc 1988;27:5–21
31. Beck AT, Steer RA, Kovacs M, Garrison B. Hopelessness and even-
tual suicide: a 10-year prospective study of patients hospitalized
with suicidal ideation. Am J Psychiatry 1985;142:559–63
32. Everson SA, Kaplan GA, Goldberg DE, Salonen JT. Hypertension
incidence is predicted by high levels of hopelessness in Finnish
men. Hypertension 2000;35:561–7
33. Everson SA, Kaplan GA, Goldberg DE, et al. Hopelessness and
4-year progression of carotid atherosclerosis. The Kuopio Ischemic
Heart Disease Risk Factor Study. Arterioscler Thromb Vasc Biol
1997;17:1490–5
34. Whipple MO, Lewis TT, Sutton-Tyrrell K, et al. Hopelessness,
depressive symptoms, and carotid atherosclerosis in women: the
Study of Women’s Health Across the Nation (SWAN) heart study.
Stroke 2009;40:3166–72
35. Dunn SL, Corser W, Stommel M, Holmes-Rovner M. Hopelessness
and depression in the early recovery period after hospitalization
for acute coronary syndrome. J Cardiopulm Rehabil 2006;26:152–9
36. Watson M, Homewood J, Haviland J. Coping response and survival
in breast cancer patients: a new analysis. Stress Health 2012;28:
376–80
37. Molassiotis A, Van Den Akker OB, Milligan DW, Goldman JM.
Symptom distress, coping style and biological variables as predic-
tors of survival after bone marrow transplantation. J Psychosom
Res 1997;42:275–85
38. Bishop FL, Yardley L, Lewith GT. Why do people use different
forms of complementary medicine? Multivariate associations
between treatment and illness beliefs and complementary medi-
cine use. Psychol Health 2006;21:683–98
39. S€ollner W, Maislinger S, DeVries A, et al. Use of complementary
and alternative medicine by cancer patients is not associated
with perceived distress or poor compliance with standard treat-
ment but with active coping behavior: a survey. Cancer
2000;89:873–80
40. Gentry-Maharaj A, Karpinskyj C, Glazer C, et al. Use and perceived
efficacy of complementary and alternative medicines after discon-
tinuation of hormone therapy: a nested United Kingdom
Collaborative Trial of Ovarian Cancer Screening cohort study.
Menopause 2015;22:384–90
41. Hamoda H, Panay N, Arya R, Savvas M. The British Menopause
Society & Women’s Health Concern 2016 recommendations on
hormone replacement therapy in menopausal women. Post
Reproductive Health 2016; 22:165–83
42. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hor-
mone therapy and health outcomes during the intervention and
extended poststopping phases of the Women’s Health Initiative
randomized trials. JAMA 2013;310:1353–68
43. Baber RJ, Panay N, Fenton A. IMS Writing Group. 2016 IMS
Recommendations on women’s midlife health and menopause
hormone therapy. Climacteric 2016;19:109–50
44. National Institute for Health and Care Excellence (NICE).
Menopause: diagnosis and management: NICE Guideline NG23.
2015
45. Nonhormonal management of menopause-associated vasomotor
symptoms: 2015 position statement of The North American
Menopause Society. Menopause 2015;22:1155–72
46. Geller SE, Studee L. Botanical and dietary supplements for meno-
pausal symptoms: what works, what does not. J Womens Health
(Larchmt) 2005;14:634–49
47. Posadzki P, Ernst E. Prevalence of CAM use by UK climacteric
women: a systematic review of surveys. Climacteric 2013;16:3–7
48. Burnell M, Gentry-Maharaj A, Ryan A, et al. Impact on mortality
and cancer incidence rates of using random invitation from popu-
lation registers for recruitment to trials. Trials 2011;12:61
49. Office for National Statistics. Ethnicity and National Identity in
England and Wales: 2011. Available at: http://www.ons.gov.uk/
peoplepopulationandcommunity/culturalidentity/ethnicity/articles/
ethnicityandnationalidentityinenglandandwales/2012-12-11
CLIMACTERIC 247
